ATE402150T1 - Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen - Google Patents
Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungenInfo
- Publication number
- ATE402150T1 ATE402150T1 AT05708792T AT05708792T ATE402150T1 AT E402150 T1 ATE402150 T1 AT E402150T1 AT 05708792 T AT05708792 T AT 05708792T AT 05708792 T AT05708792 T AT 05708792T AT E402150 T1 ATE402150 T1 AT E402150T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- pyrazolamine
- treatment
- neurodegenerative diseases
- formula
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical class NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55890404P | 2004-04-01 | 2004-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE402150T1 true ATE402150T1 (de) | 2008-08-15 |
Family
ID=34962302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05708792T ATE402150T1 (de) | 2004-04-01 | 2005-03-21 | Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7244757B2 (de) |
| EP (2) | EP1958939A3 (de) |
| JP (1) | JP2007530659A (de) |
| AT (1) | ATE402150T1 (de) |
| BR (1) | BRPI0509559A (de) |
| CA (1) | CA2561441A1 (de) |
| DE (1) | DE602005008417D1 (de) |
| ES (1) | ES2308442T3 (de) |
| MX (1) | MXPA06011351A (de) |
| WO (1) | WO2005095348A2 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7244757B2 (en) * | 2004-04-01 | 2007-07-17 | Pfizer Inc | Pyrazole-amine compounds for the treatment of neurodegenerative disorders |
| US7923465B2 (en) * | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| FR2913886B1 (fr) | 2007-03-22 | 2012-03-02 | Guerbet Sa | Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer |
| US9828344B2 (en) | 2012-06-01 | 2017-11-28 | LEIBNIZ-INSTITUT FÜR ALTERSFORSCHUNG FRITZ-LIPMANN-INSTITUT e.V. (FLI) | Inhibitors of the notch signaling pathway and secretion for use in medicine |
| SMT201800205T1 (it) | 2013-10-03 | 2018-05-02 | Kura Oncology Inc | Inibitori di erk e metodi d'uso |
| RS65966B1 (sr) * | 2018-02-16 | 2024-10-31 | Constellation Pharmaceuticals Inc | Inhibitori p300/cbp hat |
| JP2022542421A (ja) * | 2019-07-29 | 2022-10-03 | コンステレーション・ファーマシューティカルズ・インコーポレイテッド | 神経障害の治療に使用するための化合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS503340Y2 (de) * | 1971-06-17 | 1975-01-28 | ||
| US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| NZ523656A (en) | 2000-08-31 | 2004-11-26 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors |
| AU2002215053A1 (en) | 2000-11-27 | 2002-06-24 | Pharmacia Italia S.P.A. | Phenylacetamido- pyrazole derivatives and their use as antitumor agents |
| WO2003064396A1 (en) | 2002-02-01 | 2003-08-07 | Elan Pharmaceuticals, Inc. | Hydroxyalkanoyl aminopyrazoles and related compounds |
| US6974829B2 (en) | 2002-05-07 | 2005-12-13 | Elan Pharmaceuticals, Inc. | Succinoyl aminopyrazoles and related compounds |
| MXPA05003432A (es) | 2002-10-09 | 2005-07-05 | Pfizer Prod Inc | Compuestos pirazoles para el tratamiento de trastornos neurodegenerativos. |
| CA2524511A1 (en) | 2003-05-12 | 2004-11-18 | Pfizer Products Inc. | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders |
| CA2528496C (en) * | 2003-06-05 | 2011-04-12 | Elan Pharmaceuticals, Inc. | Acylated amino acid amidyl pyrazoles and related compounds |
| US7244757B2 (en) | 2004-04-01 | 2007-07-17 | Pfizer Inc | Pyrazole-amine compounds for the treatment of neurodegenerative disorders |
-
2005
- 2005-03-11 US US11/078,861 patent/US7244757B2/en not_active Expired - Fee Related
- 2005-03-21 DE DE602005008417T patent/DE602005008417D1/de not_active Expired - Fee Related
- 2005-03-21 CA CA002561441A patent/CA2561441A1/en not_active Abandoned
- 2005-03-21 MX MXPA06011351A patent/MXPA06011351A/es active IP Right Grant
- 2005-03-21 BR BRPI0509559-0A patent/BRPI0509559A/pt not_active IP Right Cessation
- 2005-03-21 JP JP2007505655A patent/JP2007530659A/ja not_active Withdrawn
- 2005-03-21 EP EP08157177A patent/EP1958939A3/de not_active Withdrawn
- 2005-03-21 ES ES05708792T patent/ES2308442T3/es not_active Expired - Lifetime
- 2005-03-21 WO PCT/IB2005/000793 patent/WO2005095348A2/en not_active Ceased
- 2005-03-21 AT AT05708792T patent/ATE402150T1/de not_active IP Right Cessation
- 2005-03-21 EP EP05708792A patent/EP1735285B1/de not_active Expired - Lifetime
-
2007
- 2007-07-05 US US11/773,831 patent/US7468386B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20070265327A1 (en) | 2007-11-15 |
| EP1735285A2 (de) | 2006-12-27 |
| JP2007530659A (ja) | 2007-11-01 |
| WO2005095348A3 (en) | 2006-03-23 |
| US7244757B2 (en) | 2007-07-17 |
| EP1735285B1 (de) | 2008-07-23 |
| BRPI0509559A (pt) | 2007-09-18 |
| EP1958939A2 (de) | 2008-08-20 |
| CA2561441A1 (en) | 2005-10-13 |
| ES2308442T3 (es) | 2008-12-01 |
| US20050222239A1 (en) | 2005-10-06 |
| US7468386B2 (en) | 2008-12-23 |
| MXPA06011351A (es) | 2006-12-15 |
| WO2005095348A2 (en) | 2005-10-13 |
| EP1958939A3 (de) | 2008-09-10 |
| DE602005008417D1 (de) | 2008-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA83899C2 (uk) | Сполуки імідазолу для лікування нейродегенеративних розладів | |
| TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
| BR0315158A (pt) | Compostos de pirazol para o tratamento de distúrbios neurodegenarativos | |
| CA2534532A1 (en) | Compounds for the treatment of neurodegenerative disorders | |
| MXPA05012196A (es) | Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos. | |
| BRPI0509504A (pt) | compostos de tiadiazol-amina para o tratamento de distúrbios neurodegenerativos | |
| TW200630374A (en) | Thiazolyldihydroindazoles | |
| MY136718A (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders | |
| DE602005008417D1 (de) | Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen | |
| TW200510351A (en) | Oxazole compounds for the treatment of neurodegenerative disorders | |
| CR9815A (es) | Compuestos de imidazol para el tratamiento de transtornos neurologicos | |
| WO2005097114A3 (en) | Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders | |
| ATE399758T1 (de) | Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten | |
| WO2005095361A8 (en) | Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders | |
| BRPI0509582A (pt) | compostos de tiazol-amina e respectivas composições farmacêuticas | |
| MY145068A (en) | Imidazole compounds for the treatment of neurodegenerative disorders | |
| DOP2004000982A (es) | Compuestos para el tratamiento de trastornos neurodegenerativos | |
| DOP2006000200A (es) | Compuestos de imidazol para el tratamiento de trastonos neurologicos | |
| EA200500382A1 (ru) | Соединения тиазола для лечения нейродегенеративных расстройств | |
| CU23591B7 (es) | Compuestos de imidazol para el tratamiento de desórdenes neurovegetativos | |
| BRPI0402756A (pt) | método para o tratamento de distúrbios cognitivos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |